Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553152 | 0.83 | CYP1A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL1553149 | 0.83 | CYP1A2 (0.41) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL28106069 | 0.81 | ADRA2C (0.49) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL6616733 | 0.78 | ADRB2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL30637279 | 0.78 | HTR2A (0.42) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL1552180 | 0.78 | SLC6A4 (0.48) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL1553138 | 0.78 | SLC6A4 (0.48) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL28253269 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B | |
| SCHEMBL465245 | 0.77 | HRH1 (0.44) | HRH1 | |
| SCHEMBL28029187 | 0.77 | HTR2A (0.40) | SLC6A2SLC6A3SLC6A4HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104903320-B | Nitrogen-containing heterocycle compound or its salt | 富士胶片株式会社 | 2018-11-13 | — | — | CN | disclosed |
| CN-106559992-A | As the bicyclic heteroaromatic derivative for condensing of kinase inhibitor | UCB生物制药私人有限公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-106507674-A | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB生物制药私人有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106459046-A | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB生物制药私人有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-100519550-C | 2-oxoindole compounds having inhibitory activity on glycogen synthase kinase 3 receptor | ASTRAZENECA AB SE (SE) | 2009-07-29 | — | — | CN | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| CN-1923812-A | New compounds | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | CN | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| CN-1642938-A | Novel compounds | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SLC6A2 3596/4885SLC6A3 3049/4885SLC6A4 3547/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | SLC6A2 2689/4885SLC6A3 3223/4885SLC6A4 3570/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SLC6A2 3596/4885SLC6A3 3049/4885SLC6A4 3547/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SLC6A2 3596/4885SLC6A3 3049/4885SLC6A4 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.